| DRUG WATCH |
|
| Year : 2021 | Volume
: 53
| Issue : 2 | Page : 157-159 |
Liposomal amphotericin B-induced reversible ototoxicity in a patient with disseminated histoplasmosis
Ramadoss Ramu1, Brijesh Sharma1, Dheeresh Karunakara1, Purnima Paliwal2, Naman Bansal1, Rajesh Satyapal Taneja1
1 Department of Medicine PGIMER and Dr. RML Hospital, New Delhi, India
2 Department of Pathology, PGIMER and Dr. RML Hospital, New Delhi, India
Correspondence Address:
Dr. Ramadoss Ramu
Department of Medicine, PGIMER and Dr. RML Hospital, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.316948
Amphotericin B (AmB) is a polyene antifungal agent used widely for systemic fungal infections. Infusion-related side effects, nephrotoxicity, and dyselectrolytemia are well-known adverse effects with the use of this drug. Liposomal preparation of AmB has less adverse events. However, ototoxicity due to AmB is scarcely mentioned in the literature. We report a case of disseminated histoplasmosis who was treated with liposomal amphotericin B (LAmB) and developed hearing loss during the treatment, which recovered after discontinuing the drug. This is a rare adverse effect of LAmB and reported only once from India, to the best of our knowledge.
[FULL TEXT] [PDF]*
|
